Domestic surgical robots impact the monopoly of "Da Vinci"
The emergence of domestic surgical robots, while pursuing high quality, further reduces economic costs and improves cost performance. It is believed that robotic surgery will "bloom everywhere" like traditional laparoscopic surgery.
Ji Mei, professor at the First Affiliated Hospital of Zhengzhou University
On October 10, a reporter from Science and Technology Daily was informed that my country's self-developed Jingfeng surgical robot completed a multi-center randomized parallel controlled clinical trial in urology last month. Officially launched in the field of gynecology. Under the guidance of Lang Jinghe, academician of the Chinese Academy of Engineering and honorary director of the Department of Obstetrics and Gynecology of Peking Union Medical College Hospital, the clinical trial was led by Meng Yuanguang, a professor at the General Hospital of the Chinese People's Liberation Army, and jointly carried out with Ji Mei, a professor at the First Affiliated Hospital of Zhengzhou University.
Domestic surgical robots are close to the international leading level
The development of medical robots can be traced back to 1985. According to application scenarios, medical robots can be divided into four categories: surgical robots, rehabilitation robots, service robots, and auxiliary robots. Surgical robots are the most dominant category, accounting for about 37% of medical robots. Among them, the "Da Vinci Surgical Robot" of the American Intuitive Surgical Company is the leader of surgical robots, accounting for half of the global surgical robot market. Compared with general minimally invasive surgery, robot-assisted surgery has the advantages of improving the effect of surgical treatment and expanding the scope of surgical treatment.
The advantages of surgical robots are obvious, but surgical robots are complicated in technology, expensive, and dependent on imports, which have become obstacles to the development of robotic surgery in my country. Therefore, it is particularly important to manufacture domestic surgical robots and carry out clinical application trials.
"From this registered clinical trial, the domestic Jingfeng surgical robot is stable and safe, and its performance is very close to the international leading level." Professor Huang Jian, chairman of the Urology Branch of the Chinese Medical Association and director of the Department of Urology of Sun Yat-sen Hospital of Sun Yat-sen University, said, " Thanks to the advantages of clearer field of view, more precise operation, and better surgical results, robot-assisted surgery will gradually replace laparoscopic surgery.”
At present, the clinical registration trial of Jingfeng surgical robot MP system has been completed, marking that the medical surgical robot system completely independently developed and produced in my country has begun to enter the clinic.
The registered clinical trial was jointly conducted by Zhang Xu, a professor at the General Hospital of the Chinese People's Liberation Army, Lin Tianxin, a professor at Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Zhou Fangjian, a professor at the Sun Yat-sen University Cancer Center, and Zhang Xuepei, a professor at the First Affiliated Hospital of Zhengzhou University.
According to experts, through the verification of this registered clinical trial, the Jingfeng surgical robot MP system can meet the requirements of complex surgeries such as prostate cancer and kidney cancer in urology surgery. The bleeding volume was small, and the postoperative prognosis of the patients was good.
Zhang Xu pointed out: "Minimally invasive, intelligent and precise surgery is the general trend. The application of surgical robots, especially domestic surgical robots, will help to simplify, standardize, standardize and homogenize complex operations."
It is expected to "bloom everywhere" like laparoscopic surgery
"This type of surgical robot has always been monopolized by imported brands, and the high surgical cost has also discouraged many patients, which to a certain extent hinders the further application and development of robotic surgery in China." CEO of Jingfeng Medical Technology Co., Ltd. Wang Jianchen said.
Meng Yuanguang said that the multi-disciplinary application of robots has been recognized, but at present it has not been popularized due to issues such as price. Domestic surgical robots have filled the domestic gap, allowing high-end resources to sink into primary medical care.
"The emergence of domestic surgical robots, while pursuing high quality, further reduces economic costs and improves cost performance. The strong landing of domestic surgical robots and the healthy competition in the industry make the price of robotic surgery more affordable to the people. I believe that robotic surgery will also be Like traditional laparoscopic surgery, it's 'blooming everywhere'." Ji Mei pointed out.
According to relevant data, the Chinese surgical robot market will increase from US$400 million in 2020 to US$3.8 billion in 2026. At the same time, with the increasing incidence of chronic diseases such as cardiovascular, neurovascular, and tumors, surgical robots will usher in a larger market.
"We look forward to the continuous innovation, improvement and improvement of domestic surgical robots, and we expect that in the near future, there will be training platforms using domestic surgical robots across the country to train more minimally invasive specialists with robot-assisted surgery technology." Sun Yat-Sen University Oncology Liu Zhuowei, a professor at the Prevention and Treatment Center, said.
Article source: Science and Technology Daily
Any information indicated by the information source as other media sources is reproduced from other media, and does not mean that this website agrees with its views. This article is reproduced for the purpose of conveying more information. If the source is marked incorrectly or violates your legal rights, please contact us, we will correct or delete it in time, thank you.